Nektar Therapeutics
Nektar Therapeutics develops medicines for immunotherapy globally. Theyre developing rezpegaldesleukin for lupus erythematosus and ulcerative colitis, and atopic dermatitis and psoriasis. Rezpegaldesleukin is in phase 2 clinical trials. NKTR-255 is an IL-15 receptor agonist in phase 1 clinical trial to treat cancer. The company has collaborations with several major pharmaceutical companies. Nektar was incorporated in 1990 and is headquartered in San Francisco, California.
Overview
Strengths
- No significant strengths identified based on the analyzed metrics.
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Price to book ratio (81.64) is significantly higher than the sector mean (24.44).
- The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.
- The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
- EBITDA Margin (0.00%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 100.0 |